Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms

Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms

Combining low-dose chemotherapies is a strategy for designing less toxic and more potent childhood cancer treatments. We examined the effects of combining the novel thiosemicarbazones, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), or its analog, di-2-pyridylketone-4,4-dimethyl-...

Full description

Bibliographic Details
Main Authors: Silvia Paukovcekova, Jan Skoda, Jakub Neradil, Erika Mikulenkova, Petr Chlapek, Jaroslav Sterba, Des R. Richardson, Renata Veselska
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
thiosemicarbazones
DpC
Dp44mT
celecoxib
temozolomide
etoposide
Online Access:https://www.mdpi.com/2072-6694/12/12/3781

Internet

https://www.mdpi.com/2072-6694/12/12/3781

Similar Items